Checkpoint Therapeutics (NASDAQ:CKPT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday.

According to Zacks, “Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. “

Separately, HC Wainwright initiated coverage on shares of Checkpoint Therapeutics in a research note on Friday, December 8th. They issued a “buy” rating and a $11.00 target price for the company.

Shares of Checkpoint Therapeutics (CKPT) traded down $0.10 during mid-day trading on Wednesday, reaching $3.28. 75,239 shares of the company traded hands, compared to its average volume of 60,814. Checkpoint Therapeutics has a 12-month low of $3.20 and a 12-month high of $15.00. The company has a market cap of $83.92 and a P/E ratio of -2.93.

WARNING: This news story was published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/01/10/zacks-investment-research-lowers-checkpoint-therapeutics-ckpt-to-hold.html.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.

Get a free copy of the Zacks research report on Checkpoint Therapeutics (CKPT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.